title: [PHARMACOLOGICAL CORRECTION OF METABOLIC DISORDERS IN CHILDREN WITH ACUTE EPSTEIN--BARR VIRAL INFECTION].
abstract: The study was aimed to investigate the influence of drug reamberin inclusion in the treatment regimen of patients with acute Epstein-Barr virus (EBV) infection on the effectiveness of therapy. Treatment results were analyzed in a group of 70 children aged 4-15 with a diagnosis of moderate to severe EBV infection. By the method of random sampling distribution, patients were divided into two comparable groups of 35 children, which were representative with respect to gender, age, date of admission, and conducted basic therapy. Patients in the control group were treated by the conventional scheme, while the main group received basic therapy with antibacterial drug (according to indication) and symptomatic agents (antipyretics, desensitizing agents, and local antiseptics for the treatment of rotor and nasopharynx) and, in addition, obtained 1.5% reamberin solution intravenously, 10 mL/kg body weight once a day at a rate of 3-4 mL/min (the treatment course did not exceed 3 days). Treatment efficacy was assessed by a decrease in the duration of intoxication symptoms, relief of their clinical manifestations, and normalization of laboratory data (including, in addition to commonly accepted data, the levels of malonic dialdehyde, ferritin, transferrin and catalase before and after treatment).The inclusion of reamberin in the therapy of acute EBV infection in children favors (in comparison to conventional treatment regimen) more pronounced and rapid decrease the intensity of the oxidative process and improves the functioning of the antioxidant system. This was manifested by normalization of immunobiochemical indicators (reduction of malonic dialdehyde and ferritin and increase in the level of catalase) and decrease in the inflammatory response (leukocytosis, ESR, and the number of atypical mononuclear cells in the blood), This resulted in more rapid relief of the clinical manifestations of infection (sore throat, hyperthermia, lymphadenopathy, and hepatomegaly) and shortened the hospital stay by 38.5% (p < 0.05).
authors.forename: E B
authors.initials: EB
authors.lastname: Kasymova
authors.forename: O A
authors.initials: OA
authors.lastname: Bashkina
authors.forename: Kh M
authors.initials: KhM
authors.lastname: Galimzyanov
authors.forename: K Zh
authors.initials: KZh
authors.lastname: Engibaryan
authors.forename: L P
authors.initials: LP
authors.lastname: Rodina
authors.forename: L S
authors.initials: LS
authors.lastname: Chanpalova
authors.forename: A L
authors.initials: AL
authors.lastname: Kovalenko
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000188:drug therapy*; D005260:Female; D004854:Herpesvirus 4, Human; D006801:Humans; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008659:Metabolic Diseases / Q000150:complications / Q000188:drug therapy*; D013386:Succinates / Q000008:administration & dosage*
chemical_list: C549374:Reamberin; D013386:Succinates; D008536:Meglumine